title: Inhibition of semicarbazide-sensitive amine oxidase attenuates myocardial ischemia-reperfusion injury in an in vivo rat model.
abstract: OBJECTIVE
  This study tested the hypothesis that the inhibition of semicarbazide-sensitive amine oxidase (SSAO) after ischemia could attenuate myocardial ischemia-reperfusion (I/R) injury.
  
  
  METHODS
  Anesthetized male Sprague-Dawley rats underwent myocardial I/R injury. Saline, semicarbazide (SCZ, 30 mg/kg), hydralazine (HYD, 10mg/kg), or LJP 1207 (30 mg/kg) was administered intraperitoneally 3 min before reperfusion. After 30 min of ischemia and 180 min of reperfusion, the myocardial infarct size was determined using nitroblue tetrazolium staining. Myocardial myeloperoxidase activity was determined through biochemical assay. HE staining was used for histopathological evaluation. Myocardial SSAO activity was assayed with high performance liquid chromatography analysis. Additionally, the endothelial expression of P-selectin was evaluated using immunohistochemistry after 30 min of ischemia and 20 min of reperfusion.
  
  
  RESULTS
  Myocardial SSAO activity was increased in myocardial I/R injury. Administration of SCZ, HYD, or LJP 1207 reduced the myocardial infarct size and decreased leukocyte infiltration and endothelial P-selectin expression in myocardial I/R injury in vivo.
  
  
  CONCLUSIONS
  These data suggest that myocardial I/R injury up-regulates myocardial SSAO activity, and the inhibition of SSAO prior to reperfusion is able to attenuate acute myocardial I/R injury.
authors.affiliation: Bioanalytical Laboratory, Shantou University Medical College, Shantou, Guangdong, PR China.
authors.forename: Wei
authors.initials: W
authors.lastname: Yang
authors.forename: Hui
authors.initials: H
authors.lastname: Li
authors.forename: Hongjun
authors.initials: H
authors.lastname: Luo
authors.forename: Wenhong
authors.initials: W
authors.lastname: Luo
mesh_terms: D006631:Amine Oxidase (Copper-Containing) / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000502:physiology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D004195:Disease Models, Animal; D006339:Heart Rate / Q000187:drug effects; D006830:Hydralazine / Q000494:pharmacology; D006834:Hydrazines / Q000494:pharmacology; D008297:Male; D009203:Myocardial Infarction / Q000378:metabolism / Q000503:physiopathology; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D009206:Myocardium / Q000201:enzymology; D019007:P-Selectin / Q000032:analysis / Q000096:biosynthesis; D009195:Peroxidase / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D012663:Semicarbazides / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D006834:Hydrazines; C506836:N'-(2-phenylallyl)hydrazine; D019007:P-Selectin; D012663:Semicarbazides; D006830:Hydralazine; C010059:carbamylhydrazine; D009195:Peroxidase; D006631:Amine Oxidase (Copper-Containing)